According to Piper Jaffray, Omnicell OMCL, PT and FY12 EPS estimates are revised.
Piper Jaffray increased the PT of Omnicell from $17 to $19 and FY12 EPS estimates from $0.69 to $0.71. The stock is currently rated as Overweight.
Omnicell closed yesterday at $16.46.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsHealth CareHealth Care TechnologyPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
